HTD- Biotech great news
Huntingdon Anticipates Strong 1999 Results
HUNTINGDON, England, Feb 8, 2000 (BUSINESS WIRE) -- Huntingdon Life Sciences Group
plc (NYSE: HTD) announced today that it anticipates releasing its 1999 results within the next two
weeks. The Company has reported three consecutive quarters of improving revenues and margins,
and remains optimistic about the fourth quarter performance of the Group. Responding to the recent
decline in the price of the Company's ordinary shares, Brian Cass, Huntingdon's Managing Director,
said "We are aware of nothing in the Company's operating performance nor in its financial condition
which would justify the recent weakening in our share price. To the contrary, we are very pleased
that our results improved each quarter in 1999, thanks in large part to the continued and increasing
support from our clients since the new management team became involved with the Company in
September 1998. We are optimistic about the prospects for 2000."
Huntingdon Life Sciences Group plc is one of the world's leading CROs providing
product development services to the pharmaceutical, agrochemical and biotechnology industries.
Huntingdon brings leading technology and capability to
support its clients in non-clinical safety testing of new compounds in early
stage development and assessment. Huntingdon operates research facilities in the
United Kingdom (Huntingdon and Eye, England) and the United States (The
Princeton Research Centre, New Jersey). |
